ABVC BioPharma(ABVC) - 2025 Q3 - Quarterly Results

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 ABVC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | Nevada | 001-40700 | 26-001465 ...